恩威医药
(301331)
| 流通市值：21.11亿 | | | 总市值：21.16亿 |
| 流通股本：1.03亿 | | | 总股本：1.03亿 |
| 利润表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 营业总收入 | 175,328,944.36 | 900,771,087.12 | 636,853,560 | 449,221,452.75 |
| 营业总成本 | 163,762,300.69 | 842,272,742.13 | 603,849,773.06 | 408,252,811.68 |
| 其他经营收益 | | | | |
| 营业利润 | 14,090,150.86 | 62,359,043.7 | 43,356,667.76 | 45,901,404.7 |
| 利润总额 | 13,882,903.43 | 64,163,756.05 | 43,187,561.47 | 45,729,439.39 |
| 净利润 | 12,504,732.32 | 51,944,936.65 | 36,584,661.67 | 38,344,181.25 |
| 每股收益 | | | | |
| 其他综合收益 | - | 0 | - | - |
| 综合收益总额 | 12,504,732.32 | 51,944,936.65 | 36,584,661.67 | 38,344,181.25 |
| 资产负债表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 流动资产: | | | | |
| 流动资产合计 | 920,020,713.92 | 975,462,846.46 | 937,260,557.13 | 956,378,438.7 |
| 非流动资产: | | | | |
| 非流动资产合计 | 578,863,880.52 | 575,199,716.74 | 559,448,194.4 | 559,606,358.59 |
| 资产总计 | 1,498,884,594.44 | 1,550,662,563.2 | 1,496,708,751.53 | 1,515,984,797.29 |
| 流动负债: | | | | |
| 流动负债合计 | 390,258,378.95 | 454,989,723.03 | 211,216,454.12 | 232,562,769.89 |
| 非流动负债: | | | | |
| 非流动负债合计 | 22,413,539.69 | 22,866,715.43 | 201,844,022.66 | 200,542,991.26 |
| 负债合计 | 412,671,918.64 | 477,856,438.46 | 413,060,476.78 | 433,105,761.15 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,086,212,675.8 | 1,072,806,124.74 | 1,083,648,274.75 | 1,082,879,036.14 |
| 股东权益合计 | 1,086,212,675.8 | 1,072,806,124.74 | 1,083,648,274.75 | 1,082,879,036.14 |
| 负债和股东权益合计 | 1,498,884,594.44 | 1,550,662,563.2 | 1,496,708,751.53 | 1,515,984,797.29 |
| 现金流量表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 180,047,207.88 | 830,274,501.92 | 617,940,375 | 425,210,134.08 |
| 经营活动现金流出小计 | 183,539,527.9 | 720,681,639.81 | 541,738,339.99 | 350,027,973.26 |
| 经营活动产生的现金流量净额 | -3,492,320.02 | 109,592,862.11 | 76,202,035.01 | 75,182,160.82 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 401,229,699.93 | 1,672,288,578.5 | 1,267,294,447.06 | 865,450,815.15 |
| 投资活动现金流出小计 | 422,926,404.29 | 1,751,116,936.08 | 1,346,711,793.66 | 904,218,278.07 |
| 投资活动产生的现金流量净额 | -21,696,704.36 | -78,828,357.58 | -79,417,346.6 | -38,767,462.92 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | - | 10,774,174.77 | - | - |
| 筹资活动现金流出小计 | 36,388,140.57 | 32,463,084.27 | 26,442,128.13 | 25,580,789.63 |
| 筹资活动产生的现金流量净额 | -36,388,140.57 | -21,688,909.5 | -26,442,128.13 | -25,580,789.63 |
| 汇率变动对现金及现金等价物的影响 | -93.5 | -136.37 | -70.8 | -25.42 |
| 现金及现金等价物净增加额 | -61,577,258.45 | 9,075,458.66 | -29,657,510.52 | 10,833,882.85 |
| 期末现金及现金等价物余额 | 236,721,989.76 | 298,299,248.21 | 259,566,279.03 | 300,057,672.4 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | 9,075,458.66 | - | 10,833,882.85 |